Table 1.
Paediatric cohort characteristics and outcomes
| Author/Date | # children on HAART | Age at initiation | Duration of follow up | CD4 at initiation | Adherence | Survival | Loss to Follow-Up |
|---|---|---|---|---|---|---|---|
| Abrams 2005 [18] | 144 | Median 19 months (Range 2 months - 12 years) |
|||||
| Van Griensven 2008 [28] | 332 | Median 7.2 years (IQR 4.5-10.4) |
Median 2.0 years (IQR 1.2-2.6) |
Median 14% (IQR 9-18%) |
49%: >95% adherence 46%: >80% adherence |
98% survival at 12 months 8 deaths (2.6% mortality) |
12 children (3.8%) |
| Eley 2004 [22] | 80 | Median 1.25 years (Range .003-12.0) |
"Most": >85% adherence | 7 deaths (8.8% mortality) | 4 children (5%) |
||
| Habibu 2006 [23]* | 52 | >95% adherence | 0 children | ||||
| Lusiama 2004 [24]* | 393 | Median 7.5 (years) (IQR 4.3-10.5) |
Median 21.9 months (IQR 7.5-25.9) |
Median 12% (IQR 7-18%) |
30 deaths (8% mortality) | 44 children (9%) |
|
| Midturi 2008 [25]* | 56 | Mean 39.6 months | Mean 14.7 months | 77.8% adherence | 1.8% mortality | 1.8% | |
| Reddi 2007 [26] | 151 | Median 5.7 years (Range 0.3-15.4) |
Median 8 months (IQR 3.5-13.5) |
Median 7.4% (IQR 2.1-13.7%) |
59.6%: no missed doses 29.8%: >95% adherence |
90.9% survival at 12 months 13 deaths (8.6% mortality) |
0 children |
| Tonwe-Gold 2009 [27] | 43 | Median 12 months (IQR 5.0-15.0) |
2 deaths (4.9% mortality) | 0 children | |||
| Van Winghem 2008 [29] | 657 | Median 5.5 years (IQR 3.2-8.7) |
Median 1.36 years (IQR 0.6-2.2) |
95.3% survival at 12 months 7 deaths (6.7% mortality) |
67 children (10.2%) |
* Indicates that this refers to a conference abstract, rather than a published journal article
Note: An empty table cell indicates none of that type of data were available in that publication